reaction). Among the compounds tested trans-5,6,6a,8,9,11a-hexahydronaphth[1',2':4,5]imidazo[2,1-b]thiazole (trans-17a) and (+/-)-5,6,6a beta,8,9,11a alpha-hexahydro-8 beta-hydroxy-9 beta-methyl-8 alpha-phenylnaphth[1',2':4,5]imidazo[2,1-b]thiazole (20a) showed the largest immunological activity in mice with a magnitude comparable to that of levamisole and were found to be considerably less toxic than levamisole
一系列5,6,6a,8,9,11a-六氢
萘[1',2':4,5]
咪唑[2,qb]
噻唑(17和20)和5,6,6a,9,10,已合成了11a-六氢
萘[2',1':4,5]
咪唑并[2,1-b]
噻唑,其中顺式和/或反式-1,2-二
氨基-
1,2,3,4-四氢萘为关键中间体并随后评估其免疫活性(对
抗体形成和迟发型超敏反应的影响)。在测试的化合物中,反式-5,6,6a,8,9,11a-六氢
萘[1',2':4,5]
咪唑[2,1-b]
噻唑(反式17a)和(+/-) -5,6,6a beta,8,9,11a alpha-hexahydro-8 beta-hydroxy-9 beta-methyl-8 alpha-phenylnaphth [1',2':4,5]
咪唑[2,1-b]
噻唑(20a)在小鼠中显示出最大的免疫活性,其程度与
左旋咪唑相当,并且在急性毒理学研究中发现其毒性明显低于
左旋咪唑。通过X射线晶体学确定18a和20a的结构。